Dr Armando Orlandi speaks to ecancer about ERMES, a phase III study which looked at FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab alone in first-line therapy of RAS and BRAF wild-type metastatic colorectal cancer patients.
The ERMES study results did not demonstrate non-inferiority of maintenance with cetuximab alone. The higher-than-expected drop-out rate and subsequent reduced statistical power might have impaired the results. The ITT analysis and overall survival results are suggestive for a strategy of de-escalation treatment with only cetuximab.
Ongoing translational analyses might allow to select patients benefitting from de-escalation strategy.
ERMES study does not demonstrate non-inferiority of maintenance